[HIV-STD-Prevention] Weekly Prevention Resources - 8/22/25 #u#

[Shelley Pearson (she/her)]

Hello, HIV and STI Prevention partners,

Welcome to this week’s HIV/STI Prevention listserv email! Please email me at shelley.m.pearson at oha.oregon.gov<mailto:shelley.m.pearson at oha.oregon.gov> with any feedback about the listserv, with announcements/resources to share, if you have colleagues who would like to be added to the list, or if you have questions about the items in this week’s email.

In this week’s email:

  *   Oregon HIV Epidemiological Profile 2023 Now Available
  *   A New Option for HIV PrEP: Lenacapavir

________________________________

The Oregon HIV Epidemiological Profile is produced by the HIV/STD/TB (HST) Program, Oregon Health Authority. Oregon-specific HIV data are collected from multiple sources including public and private laboratories, local health departments, case interviews, medical record review and death records. These data describe the demography, geographic distribution, and behavioral factors that characterize people living with HIV in Oregon. The Oregon HIV Epidemiological Profile 2023<https://public.tableau.com/app/profile/oregon.health.authority.public.health.divison/viz/HIVinOregon2023_17551989964030/HomePage> was published in 2025 based on data which includes HIV diagnoses through 12/31/2023. The HIV Epidemiologic Profile summarizes key aspects of the HIV epidemic in Oregon.

Links to other data dashboards can be found here<https://www.oregon.gov/oha/PH/DISEASESCONDITIONS/HIVSTDVIRALHEPATITIS/Pages/countyleveldata.aspx>.

________________________________

In June 2025, the FDA approved Lenacapavir for Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents. Lenacapavir is a capsid inhibitor, a novel class of antiretroviral medication that disrupts multiple stages of the HIV lifecycle. It was first approved in 2022 for the treatment of multidrug-resistant HIV-1.

The newly approved PrEP formulation of Lenacapavir (Yeztugo) is administered as a subcutaneous injection every six months, making it the longest-acting PrEP option available. Lenacapavir joins a growing list of HIV prevention tools, including:
·         Daily oral medications:
o    Emtricitabine/tenofovir alafenamide (Descovy)
o    Emtricitabine/tenofovir disoproxil fumarate (Truvada)
·         Long-acting injectable:
o    Cabotegravir (Apretude), given every two months

All forms of HIV PrEP should be prescribed as part of a comprehensive prevention strategy, which includes regular HIV testing, STI screening, and risk-reduction counseling. Click this link<https://clinicalinfo.hiv.gov/en/drugs/lenacapavir/patient> to learn more about Lenacapavir.

________________________________
Shelley Pearson
Pronouns: she/her/hers
HIV/STI Administrative and Communications Specialist
OREGON HEALTH AUTHORITY
Public Health Division
shelley.m.pearson at oha.oregon.gov<mailto:shelley.m.pearson at dhsoha.state.or.us>
Phone: 503-381-6173
Fax: 971-673-0178

[cid:image001.png at 01DC1341.C47BC540]<http://www.endhivoregon.org/>



-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://omls.oregon.gov/pipermail/hiv-std-prevention/attachments/20250822/28ca8b61/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.png
Type: image/png
Size: 17451 bytes
Desc: image001.png
URL: <https://omls.oregon.gov/pipermail/hiv-std-prevention/attachments/20250822/28ca8b61/attachment-0001.png>